A study reports that post-treatment circulating tumor DNA levels may better predict recurrence in HER2-positive breast cancer patients than current pCR measures.
Read More
Labcorp has expanded its MRD testing portfolio with new personalized panels for breast and lung cancer and nationwide whole-genome MRD testing for stage III colon cancer, enabling earlier detection of recurrence via ctDNA analysis.
Read More
National study finds 17% of patients request tests based on social media content, while 93% expect doctors to order tests upon request.
Read More
Special issue explores advances in noninvasive prenatal screening, molecular diagnostics, and care disparities affecting perinatal outcomes.
Read More
Study finds noninvasive prenatal screening using low-cost whole genome sequencing can identify mothers at risk for transmitting virus that causes hearing loss in newborns.
Read More